A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer.

Trial Profile

A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Mar 2016 Results (pooled analysis of this and other study, n = 98) assessing exposure-response relationship presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jul 2012 Planned end date changed from 1 Aug 2013 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top